Teodora Andonova holds a Ph.D. in Medicine from Karolinska Institutet and is driven by a passion for advancing life science research and innovation. During her Ph.D. studies, Teodora focused on exploring new treatments for neuroblastoma and medulloblastoma, specifically the neuritogenesis pathways.
Teodora believes that research should have a real-world impact on society, which she has pursued through various courses such as "Exploring Entrepreneurial Opportunities in Research" at the Stockholm School of Entrepreneurship.
At Sciety, Teodora is responsible for meeting with life science companies and evaluating their research and potential to identify the ones with the potential to become leaders in their field.
Teodora has several published papers to her credit, including studies on the effects of targeting the fibroblast growth factor receptor (FGFR) and phosphoinositide 3-kinase (PI3K) signaling pathways in medulloblastoma cell lines and the inhibition of Rho-associated kinase in suppressing medulloblastoma growth.